Form 4 for GILD Gilead Sciences
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-10 · accession 0001127602-24-009542 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-11 | 2024-03-10 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | — | +9,844 | 123.0K | +9% | — |
| D | 2024-03-11 | 2024-03-10 | GILD | Mercier Johanna | Chief Commercial Off | F - Tax | $75.12 | -4,559 | 118.4K | -4% | -$342.5K |
| DM | 2024-03-11 | 2024-03-10 | GILD | Mercier Johanna | Chief Commercial Off | A - Grant | $0.00 | +105.3K | 88.0K | New | $0 |
| DM | 2024-03-11 | 2024-03-10 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | — | -9,844 | 30.1K | -25% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-10 | M | A | 3,025 | — | 116,172 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2024-03-10 | F | D | 4,559 | $75.12 | 118,432 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-10 | M | A | 6,819 | — | 122,991 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Restricted Stock Unit | 2024-03-10 | A | A | 17,305 | — | 47,448 | D | — · — to — | 17,305 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 3,025 | — | 36,962 | D | — · — to — | 3,025 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |
| 6 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 6,819 | — | 30,143 | D | — · — to — | 6,819 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-03-10 | A | A | 87,970 | $0.00 | 87,970 | D | $75.12 · — to 2034-03-10 | 87,970 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |